Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10335452 | MALLINCKRODT IRELAND | Method of treating patients with hepatorenal syndrome type 1 |
Apr, 2037
(12 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Sep 14, 2027 |
Orphan Drug Exclusivity(ODE-406) | Sep 14, 2029 |
Drugs and Companies using TERLIPRESSIN ACETATE ingredient
NCE-1 date: 14 September, 2026
Market Authorisation Date: 14 September, 2022
Treatment: A method to improve kidney function in adults with hepatorenal syndrome with rapid reduction in kidney function
Dosage: POWDER;INTRAVENOUS